Compare BSAC & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | MEDP |
|---|---|---|
| Founded | 1977 | 1992 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 16.1B |
| IPO Year | 1994 | 2016 |
| Metric | BSAC | MEDP |
|---|---|---|
| Price | $35.08 | $606.70 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 12 |
| Target Price | $29.50 | ★ $479.64 |
| AVG Volume (30 Days) | ★ 270.6K | 200.5K |
| Earning Date | 01-30-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | 22.83 | ★ 25.36 |
| EPS | 0.01 | ★ 14.32 |
| Revenue | ★ $2,560,142,282.00 | $2,358,373,000.00 |
| Revenue This Year | $35.78 | $21.43 |
| Revenue Next Year | $6.84 | $11.99 |
| P/E Ratio | ★ $13.63 | $43.34 |
| Revenue Growth | 10.15 | ★ 13.88 |
| 52 Week Low | $19.16 | $250.05 |
| 52 Week High | $34.26 | $628.92 |
| Indicator | BSAC | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 71.84 | 55.50 |
| Support Level | $32.17 | $590.00 |
| Resistance Level | $33.34 | $624.00 |
| Average True Range (ATR) | 0.81 | 20.01 |
| MACD | 0.17 | 1.33 |
| Stochastic Oscillator | 95.89 | 69.05 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.